

Gambro gets European approval of new dialysis solution

Stockholm, Sweden - Gambro AB (OM Stockholm Exchange: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that it has received European approval of a new solution product for peritoneal dialysis. It is a new unique “three-in-one” product concept which has been approved by the EEC Health Authorities through the mutual recognition procedure. The new product is part of Gambro’s expansion strategy in the peritoneal sector based on innovative systems and products for this market which has a total global market value of about USD 1.7 billion. The new product concept derives from Gambro’s leading research on glucose degradation.

The product is called “Gambrosol® trio™” and is a polymer bag with a highly advanced design and which is handling the delicately composed solutions needed for peritoneal dialysis treatment. The bag is divided into three compartments. One compartment contains a mixture of lactate, sodium, calcium, chloride and magnesium. The two other compartments contain concentrated glucose and sodium chloride solutions. By breaking one or two frangible pins at the time of use, the patient will get access to the specific glucose concentration needed. Previously patients or hospitals had to store and use two or three different types of bags with different glucose concentrations.

Peritoneal dialysis can be performed at home, at work, when traveling or at a hospital or a clinic and involves substantial quantities of disposables including dialysis solutions. The new product tremendously simplifies the logistics of peritoneal products for home patients, clinics, hospitals as well as for Gambro. The sales of the Gambrosol® trio™ product in European markets will start during the second quarter this year.

Gambro Renal Products

Gambro has a global leading position in products and systems for renal care including hemodialysis, peritoneal dialysis and renal intensive care. Gambro Renal Products has annual sales of about USD 900 M and has about 6,000 employees. Products are marketed under the Gambro and Hospal brands and mainly include filters, machines, concentrates and bloodlines for dialysis. Products and services are sold in more than 90 countries including own sales organizations in 29 countries. Development of products and production technology is focused into product centers of excellence in Germany, Italy and Sweden. The global manufacturing organization includes sites in France, Germany, Italy, Sweden, Mexico, USA, Japan, China, South Korea and Australia. Research is performed by groups covering the main areas biology, medicine, treatment systems, membranes and devices. Research groups are located in Germany, France and Sweden.

For further information please contact:

Bengt Mod  r, Senior Vice President, Corporate Communications, tel. +46-8-613 65 00,
+46-70-513 65 33

Anna Augustson, European Investor Relations Manager, tel. +46-8-613 65 35,
+46-70-513 65 34

Nina Pawlak, Citigate Dewe Rogerson, New York , tel. +1-212-419 4258, +1-917-302-1717

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology (BCT). Gambro is one of the leading providers of kidney dialysis services in the world. Gambro treats about 44,200 patients in 580 clinics worldwide. Renal care products comprise dialyzers, dialysis machines, blood lines and dialysis concentrates. BCT includes products for the separation and handling of blood components. The group, with revenue of approximately SEK 20 billion (USD 2.2 billion), has approximately 17,000 employees in some 40 countries.

Gambro AB

A public company (publ)
Reg no. 556041-8005
Hamngatan 2, P O Box 7373
SE-103 91 Stockholm
Sweden
Tel +46 8-613 65 00
Fax +46 8-611 28 30
info@gambro.com
www.gambro.com